Background Computed tomography (CT) scans are routinely obtained in oncology and
provide measures of muscle and adipose tissue predictive of morbidity and mortality …

Background Within colorectal cancer, the systemic inflammatory response (SIR) and CT‐
derived body composition, particularly the loss of lean muscle mass, are independently …

Introduction There is a growing number of publications highlighting sarcopenia and
myosteatosis as poor prognosic factors for treatment results in oncological patients. The …

Patients with colorectal cancer (CRC) often exhibit changes in body composition (BC) which
are associated with poorer clinical outcomes. Many studies group colon and rectal cancers …

Background & aims Myosteatosis, excess muscle fat infiltration, is a novel prognostic factor
in cancer patients. To define myosteatosis, skeletal muscle radiodensity (SMD) is most …

Background Myosteatosis and systemic inflammation are well‐known prognostic factors in
patients with colorectal cancer (CRC). The serum albumin level is a reflection of malnutrition …

Objective: To determine the relationship between BC, specifically low skeletal muscle mass
(sarcopenia) and poor muscle quality (myosteatosis) and outcomes in emergency …

Chemotherapy dosing is traditionally based on body surface area calculations; however,
these calculations ignore separate tissue compartments, such as the lean body mass (LBM) …

Background Although skeletal muscle index (SMI) and radiodensity (SMD) are well‐known
prognostic factors, the clinical impact of the integrated measure, known as skeletal muscle …

Objectives Gastric cancer is among the most common and lethal cancers worldwide.
Recently, studies have reported that myosteatosis is a prognosticator for adverse survival …